Scholarlink

<p>The activity of chlonisol {2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol} was studied with peroral as compared to parenteral (intraperitoneal or intravenous) administration on various transplanted tumors (melanoma B16, Ehrlich’s carcinoma, lymphosarcoma LIO-1) in mice for a more complete characterization of it as a potential antitumor compound. Tumors were transplanted not only subcutaneously but also intracranially (into the cerebral hemispheres). The criteria for evaluating the drug activity were tumor growth inhibition or overall survival of tumor-bearing animals. Chlonisol demonstrated high antitumor activity not inferior in effect to parenteral administration of the drug when administered perorally to mice with tumors transplanted subcutaneously or intracranially. The effectiveness of peroral administration of chlonisol was statistically significantly higher than that of the comparison drug lomustine (<i>per os</i>). The introduction into clinical practice of an antitumor drug that is active in both its parenteral and peroral dosage forms may be an important advantage of chlonisol.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of Peroral Administration of Chlonisol in the Experimental Treatment of Tumors

  • 期刊论文

  • 发表日期：

    2025年11月1日

查看全文
  • V. A. Alexandrov,
  • G. V. Tochilnikov,
  • Yu. G. Zmitrichenko,
  • E. V. Tkachenko,
  • A. N. Stukov,
  • O. A. Belyaeva,
  • E. V. Bashkatova,
  • V. G. Dranishnikov,
  • T. Yu. Semiglazova

摘要

The activity of chlonisol {2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol} was studied with peroral as compared to parenteral (intraperitoneal or intravenous) administration on various transplanted tumors (melanoma B16, Ehrlich’s carcinoma, lymphosarcoma LIO-1) in mice for a more complete characterization of it as a potential antitumor compound. Tumors were transplanted not only subcutaneously but also intracranially (into the cerebral hemispheres). The criteria for evaluating the drug activity were tumor growth inhibition or overall survival of tumor-bearing animals. Chlonisol demonstrated high antitumor activity not inferior in effect to parenteral administration of the drug when administered perorally to mice with tumors transplanted subcutaneously or intracranially. The effectiveness of peroral administration of chlonisol was statistically significantly higher than that of the comparison drug lomustine (per os). The introduction into clinical practice of an antitumor drug that is active in both its parenteral and peroral dosage forms may be an important advantage of chlonisol.